For thousands of women treated for gynecologic cancers each year, surviving cancer is only part of the journey. Surgery, chemotherapy and radiation often trigger abrupt menopause, bringing debilitating hot flashes, sleep disruption, sexual dysfunction, bone loss and cardiovascular risks at an age when many women would otherwise still have normal ovarian function.

Yet despite decades of accumulating evidence, many patients — and even some clinicians — remain hesitant to consider hormone replacement therapy (HRT), fearing it could increase the risk of cancer recurrence.

A recent comprehensive review led by Dr. Pedro Ramirez, chair of Obstetrics and Gynecology at Houston Methodist, argues it's time to update that conversation.

Published in the International Journal of Gynecological Cancer, the review synthesizes current evidence on HRT use across endometrial, ovarian, cervical, vulvar and vaginal cancers, providing practical guidance on which patients can safely receive hormone therapy and where caution remains warranted.

"Many of the concerns surrounding hormone replacement therapy have persisted far longer than the evidence supporting them," explains Dr. Ramirez. "With this review, we're trying to move clinicians away from decisions based on outdated assumptions and toward decisions based on current data."

The lingering shadow of an outdated warning

Ramirez says much of today's uncertainty can be traced back to the Women's Health Initiative (WHI) study published more than two decades ago. Early interpretations of those findings led to widespread concern about hormone therapy and ultimately prompted a black box warning that dramatically reduced HRT use among menopausal women.

Subsequent analyses have substantially refined those conclusions, demonstrating that risks vary significantly based on a woman's age, time since menopause and the specific hormone regimen used. Those reevaluations prompted a removal of the original black box warning, yet misconceptions continue to influence care.

That uncertainty becomes even more consequential for women treated for gynecologic cancers, many of whom experience sudden, treatment-induced menopause.

Unlike natural menopause, surgical removal of the ovaries or damage from chemotherapy or pelvic radiation can produce an abrupt loss of estrogen, often resulting in more severe symptoms and long-term health consequences.

"These are women in their 30s or 40s who suddenly go from normal ovarian function one day to complete menopause the next," says Dr. Ramirez. "They've overcome cancer, but now they're asking about their quality of life. That's an incredibly important conversation."

Evidence supports hormone therapy for many survivors

The review concludes that systemic HRT can be safely offered to many women with low-risk, early-stage endometrial cancer, most ovarian cancer subtypes, cervical cancer regardless of histology, and vulvar and vaginal cancers. Importantly, available evidence has not demonstrated higher recurrence rates or worse survival in these groups.

One of the strongest examples involves early-stage endometrial cancer. Although these tumors frequently express estrogen receptors, prospective and observational studies have consistently failed to show increased recurrence among women receiving hormone therapy after treatment.

[blockQuote]

Similarly, women with the most common high-grade serous ovarian cancers generally appear to be appropriate candidates for HRT, while cervical cancer survivors face essentially no known oncologic risk from hormone replacement.

Individualized care remains essential

The review also emphasizes that HRT is not appropriate for everyone. Women with advanced or non-endometrioid endometrial cancers, uterine sarcomas and certain rare ovarian tumors — particularly granulosa cell tumors — require more individualized discussions because of limited evidence or biologic concerns.

For patients who cannot or prefer not to take systemic hormones, the review also outlines a growing menu of alternatives, including localized vaginal estrogen, vaginal dehydroepiandrosterone, moisturizers, lubricants, cognitive behavioral therapy, gabapentin, selective serotonin reuptake inhibitors and newer non-hormonal therapies targeting vasomotor symptoms.

Ultimately, Dr. Ramirez hopes the review gives clinicians confidence to revisit conversations that have too often been avoided.

"Our goal isn't to recommend hormone therapy for everyone. It's to make sure women receive counseling that's grounded in today's evidence rather than fears from decades ago. When we do that, we can better balance oncologic safety with quality of life."